3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
6
Ovarian Neoplasms
4
Neoplasms
3
Endometrial Neoplasms
3
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Bulbo-Spinal Atrophy, X-Linked
1
Biliary Tract Neoplasms
1
Advanced Breast Cancer
1
Adenocarcinoma of Lung
1
Interventions
enzalutamide
3
abiraterone
2
ostarine
1
exemestane
1
darolutamide
1
Prednisolone
1
Docetaxel
1
AZD5305
1
AZD3514
1
5'-ACCaagtttcttcAGC-3'
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Bulbo-Spinal Atrophy, X-Linked
×
AZD5305
×
Clear all
NCT07336446
2026-05-01
ANDROMEDA
AstraZeneca
Phase 1/2
Recruiting
300 enrolled